Prelude Therapeutics Incorporated PRLD

$ 1.18 32.32%

Quarterly report 2024-Q3
added 11-06-2024

Prelude Therapeutics Incorporated Financial Statements 2011-2024 | PRLD

Annual Financial Statements Prelude Therapeutics Incorporated

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	211 M	306 M	407 M	207 M	-	-	-	-	-	-	-	-	-
Shares	60.4 M	47.4 M	46 M	3.19 M	-	-	-	-	-	-	-	-	-
Historical Prices	3.49	6.46	8.83	62.3	-	-	-	-	-	-	-	-	-
Net Income	-122 M	-115 M	-112 M	-56.9 M	-27.6 M	-14.7 M	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-132 M	-124 M	-114 M	-58.8 M	-28.1 M	-	-	-	-	-	-	-	-
Interest Expense	10.4 M	8.1 M	2.04 M	1.83 M	539 K	-	-	-	-	-	-	-	-
EBITDA	-131 M	-122 M	-113 M	-58.2 M	-27.7 M	-14.8 M	-	-	-	-	-	-	-
Operating Expenses	132 M	124 M	114 M	58.8 M	28.1 M	15 M	-	-	-	-	-	-	-
General and Administrative Expenses	28.9 M	30.7 M	27 M	10.6 M	3.83 M	2.35 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Prelude Therapeutics Incorporated

	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	75.9 M	75.8 M	75.7 M	67.6 M	56.2 M	47.7 M	-	47.4 M	47.3 M	47.1 M	-	46.3 M	46.1 M	45.1 M	-	3.19 M	2.07 M	1.86 M	-	1.71 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-32.3 M	-34.7 M	-31.4 M	-30.6 M	-30.4 M	-27.7 M	-	-30 M	-27.4 M	-29.5 M	-	-30.7 M	-26.9 M	-21.3 M	-	-16.8 M	-11.4 M	-9.51 M	-	-6.73 M	-5.56 M	-5.24 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-34.4 M	-37.2 M	-34.3 M	-33.4 M	-32.4 M	-29.1 M	-	-30.4 M	-29.5 M	-30.3 M	-	-30.8 M	-27.9 M	-22 M	-	-18.1 M	-11.4 M	-9.74 M	-	-6.88 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	2.1 M	2.42 M	2.91 M	2.78 M	1.97 M	1.4 M	-	448 K	2.09 M	823 K	-	149 K	1.06 M	667 K	-	1.38 M	28 K	226 K	-	150 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-33.9 M	-	-	-28.8 M	-	-29.4 M	-28.8 M	-30 M	-	-30.2 M	-27.6 M	-21.8 M	-	-17.7 M	-11.2 M	-9.6 M	-	-6.63 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	37.4 M	37.2 M	34.3 M	33.4 M	32.4 M	29.1 M	-	30.4 M	29.5 M	30.3 M	-	30.8 M	27.9 M	22 M	-	18.1 M	11.4 M	9.74 M	-	6.88 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	7.92 M	7.66 M	6.93 M	7.12 M	7.43 M	7.28 M	-	7.52 M	8.15 M	7.47 M	-	8.12 M	5.51 M	5.5 M	-	2.85 M	1.66 M	1.2 M	-	1.39 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency